The present invention provides a new crystal form of5-((2-(6-amino)9H-purin-9-yl)ethyl)amino)pentan- 1-ol,which has a relatively better effectin selectively inhibiting adenylate cyclase 1 and is capable of preparing amedicament for treating neuropathic pain and/or inflammatory pain.